Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - THERAGENICS CORPa6709952ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549
______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report: May 5, 2011

THERAGENICS CORPORATION®

(Exact name of registrant as specified in charter)


Delaware

001-14339

58-1528626

(State of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

5203 Bristol Industrial Way

Buford, Georgia 30518

(Address of principal executive offices / Zip Code)

(770) 271-0233
(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 2.02.         Results of Operations and Financial Condition.

        On May 5, 2011, Theragenics Corporation (the “Company”) issued a press release regarding its consolidated financial results for the first quarter ended March 31, 2011. The Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

        The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 

Theragenics Corporation

 

(Registrant)

 

Dated: May 5, 2011

 

 

By: /s/ M. Christine Jacobs

M. Christine Jacobs

Chief Executive Officer


EXHIBIT INDEX

Exhibit No.

Description

 

99.1

Press Release, dated May 5, 2011 of Theragenics Corporation.